Prognostic significance of IL-17 mRNA expression in peritoneal lavage in gastric cancer patients who underwent curative resection

Iida,Takeshi; Iwahashi,Makoto; Katsuda,Masahiro; Ishida,Koichiro; Nakamori,Mikihito; Nakamura,Masaki; Naka,Teiji; Ojima,Toshiyasu; Ueda,Kentaro; Hayata,Keiji; Yasuoka,Hironao; Yamaue,Hiroki

doi:10.3892/or.2013.2911

Prognostic significance of IL-17 mRNA expression in peritoneal lavage in gastric cancer patients who underwent curative resection

Authors:
- Takeshi Iida
- Makoto Iwahashi
- Masahiro Katsuda
- Koichiro Ishida
- Mikihito Nakamori
- Masaki Nakamura
- Teiji Naka
- Toshiyasu Ojima
- Kentaro Ueda
- Keiji Hayata
- Hironao Yasuoka
- Hiroki Yamaue
View Affiliations

Affiliations: Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama 641-8510, Japan, Division of Pathology, Department of Clinical Laboratory Medicine, School of Medicine, Wakayama Medical University, Wakayama 641-8510, Japan
Published online on: December 10, 2013 https://doi.org/10.3892/or.2013.2911
Pages: 605-612

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peritoneal dissemination is frequently detected in patients with advanced gastric cancer. The peritoneal cavity is a compartment in which an immunologic host-tumor interaction can occur. There are no reports on the relationship between IL-17 expression in peritoneal lavage and prognosis in gastric cancer patients. Therefore, we investigated the expression of IL-17 mRNA in peritoneal lavage from gastric cancer patients and assessed the association of its expression with clinicopathological parameters and prognosis. Peritoneal lavage was obtained from 114 patients with gastric cancer at initial surgery. Seventy-nine patients underwent curative resection. Among these 79 patients, IL-17 mRNA expression was associated with the depth of tumor invasion (p<0.05). Twelve of the 79 patients who underwent curative resection died, and 9 of those 12 developed peritoneal metastasis. Notably, among the 79 patients who underwent curative resection, those with high expression of IL-17 mRNA in peritoneal lavage had significantly prolonged survival when compared to these patients with low expression of IL-17 mRNA in peritoneal lavage (p<0.05) as evidence by the survival curves. In a multivariate analysis, low expression of IL-17 mRNA in peritoneal lavage and tumor size were found to be independent significant predictive factors for prognosis (HR, 7.91; 95% CI, 1.65-38.03) in the patients who underwent curative resection. IL-17 mRNA expression in peritoneal lavage is a reliable prognostic factor for patients undergoing curative resection for gastric cancer. Low IL-17 expression in the peritoneal cavity may correlate with cancer development in the peritoneal cavity in patients with gastric cancer.

View Figures

View References

1	Takahashi I, Matsusaka T, Onohara T, et al: Clinicopathological features of long-term survivors of scirrhous gastric cancer. Hepatogastroenterology. 47:1485–1488. 2000.PubMed/NCBI
2	Ito S, Nakanishi H, Kodera Y, Mochizuki Y, Tatemastu M and Yamamura Y: Prospective validation of quantitative CEA mRNA detection in peritoneal washes in gastric carcinoma patients. Br J Cancer. 93:986–992. 2005. View Article : Google Scholar : PubMed/NCBI
3	Bonenkamp JJ, Songun I, Hermans J and van de Velde CJ: Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg. 83:672–674. 1996. View Article : Google Scholar : PubMed/NCBI
4	Kodera Y, Nakanishi H, Yamamura Y, et al: Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. Int J Cancer. 79:429–433. 1998. View Article : Google Scholar
5	Fujii S, Kitayama J, Kaisaki S, et al: Carcinoembryonic antigen mRNA in abdominal cavity as a useful predictor of peritoneal recurrence of gastric cancer with serosal exposure. J Exp Clin Cancer Res. 21:547–553. 2002.PubMed/NCBI
6	Tokuda K, Natsugoe S, Nakajo A, et al: Clinical significance of CEA-mRNA expression in peritoneal lavage fluid from patients with gastric cancer. Int J Mol Med. 11:79–84. 2003.PubMed/NCBI
7	Boku T, Nakane Y, Minoura T, et al: Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer. Br J Surg. 77:436–439. 1990. View Article : Google Scholar : PubMed/NCBI
8	Kodera Y, Nakanishi H, Ito S, et al: Quantitative detection of disseminated free cancer cells in peritoneal washes with real-time reverse transcriptase-polymerase chain reaction: a sensitive predictor of outcome for patients with gastric carcinoma. Ann Surg. 235:499–506. 2002. View Article : Google Scholar
9	Oyama K, Terashima M, Takagane A, Maesawa C, et al: Prognostic significance of peritoneal minimal residual disease in gastric cancer detected by reverse transcription-polymerase chain reaction. Br J Surg. 91:435–443. 2004. View Article : Google Scholar
10	Zeimet AG, Widschwendter M, Knabbe C, et al: Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol. 16:1861–1868. 1998.PubMed/NCBI
11	Majima T, Ichikura T, Seki S, Takayama E, Hiraide H and Mochizuki H: Interleukin-10 and interferon-gamma levels within the peritoneal cavity of patients with gastric cancer. J Surg Oncol. 78:124–130. 2001. View Article : Google Scholar : PubMed/NCBI
12	Zhang B, Rong G, Wei H, et al: The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun. 374:533–537. 2008. View Article : Google Scholar : PubMed/NCBI
13	Maruyama T, Kono K, Mizukami Y, et al: Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci. 101:1947–1954. 2010.
14	Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J and Wang RF: Generation and regulation of human CD4⁺ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA. 105:15505–15510. 2008. View Article : Google Scholar : PubMed/NCBI
15	Langowski JL, Zhang X, Wu L, et al: IL-23 promotes tumour incidence and growth. Nature. 442:461–465. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kato T, Furumoto H, Ogura T, et al: Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun. 282:735–738. 2001. View Article : Google Scholar : PubMed/NCBI
17	Sfanos KS, Bruno TC, Maris CH, et al: Phenotypic analysis of prostate-infiltrating lymphocytes reveals T_H17 and T_reg skewing. Clin Cancer Res. 14:3254–3261. 2008. View Article : Google Scholar : PubMed/NCBI
18	Numasaki M, Fukushi J, Ono M, et al: Interleukin-17 promotes angiogenesis and tumor growth. Blood. 101:2620–2627. 2003. View Article : Google Scholar : PubMed/NCBI
19	Benchetrit F, Ciree A, Vives V, et al: Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 99:2114–2121. 2002. View Article : Google Scholar : PubMed/NCBI
20	Zou W and Restifo NP: T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol. 10:248–256. 2010. View Article : Google Scholar : PubMed/NCBI
21	Iida T, Iwahashi M, Katsuda M, et al: Tumor-infiltrating CD4⁺ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer. Oncol Rep. 25:1271–1277. 2011.
22	Kryczek I, Wei S, Zou L, et al: Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 178:6730–6733. 2007. View Article : Google Scholar : PubMed/NCBI
23	Lissoni P, Mandalà M, Curigliano G, et al: Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. Oncology. 60:308–312. 2001. View Article : Google Scholar : PubMed/NCBI
24	Lenzi R, Rosenblum M, Verschraegen C, et al: Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res. 8:3686–3695. 2002.PubMed/NCBI
25	Fu QG, Meng FD, Shen XD and Guo RX: Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. World J Gastroenterol. 8:1019–1022. 2002.
26	Ye ZJ, Zhou Q, Gu YY, et al: Generation and differentiation of IL-17-producing CD4⁺ T cells in malignant pleural effusion. J Immunol. 185:6348–6354. 2010. View Article : Google Scholar : PubMed/NCBI
27	Derhovanessian E, Adams V, Hähnel K, et al: Pretreatment frequency of circulating IL-17⁺ CD4⁺ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer. 125:1372–1379. 2009.PubMed/NCBI
28	Kryczek I, Banerjee M, Cheng P, et al: Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 114:1141–1149. 2009. View Article : Google Scholar : PubMed/NCBI
29	Zhang JP, Yan J, Xu J, et al: Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 50:980–989. 2009. View Article : Google Scholar : PubMed/NCBI
30	Liu J, Duan Y, Cheng X, et al: IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 407:348–354. 2011. View Article : Google Scholar : PubMed/NCBI
31	Zhuang Y, Peng LS, Zhao YL, Shi Y, Mao XH, et al: CD8⁺T cells that produce interleukin-17 regulate myeloid-derived suppressor cells and are associated with survival time of patients with gastric cancer. Gastroenterology. 143:951.e8–962.e8. 2012.PubMed/NCBI